Insider Selling: Gilead Sciences (NASDAQ:GILD) Insider Sells $432,660.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $144.22, for a total value of $432,660.00. Following the completion of the transaction, the insider owned 116,684 shares in the company, valued at $16,828,166.48. This represents a 2.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Johanna Mercier also recently made the following trade(s):

• On Monday, August 17th, Johanna Mercier sold 28,000 shares of Gilead Sciences stock. The stock was sold at an average price of $137.64, for a total value of $3,853,920.00.

Gilead Sciences Price Performance

Shares of GILD stock opened at $150.11 on Friday. Gilead Sciences, Inc. has a 1-year low of $108.46 and a 1-year high of $157.29. The stock’s 50-day moving average is $139.98 and its 200 day moving average is $136.32. The company has a market cap of $186.13 billion, a P/E ratio of -56.22 and a beta of 0.33. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. During the same period in the previous year, the company posted $2.01 earnings per share. The firm’s revenue was up 10.6% on a year-over-year basis. Research analysts predict that Gilead Sciences, Inc. will post -0.48 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Analysts Set New Price Targets

Several analysts have recently commented on GILD shares. Morgan Stanley decreased their price objective on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a report on Monday, July 27th. Zacks Research upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 31st. Weiss Ratings raised Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday. Leerink Partners lowered Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $146.00 to $127.00 in a research note on Tuesday, July 21st. Finally, Barclays decreased their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $158.78.

Institutional Trading of Gilead Sciences

Several large investors have recently added to or reduced their stakes in the company. Security National Bank of Sioux City Iowa IA acquired a new stake in shares of Gilead Sciences during the second quarter worth about $63,000. Anchor Investment Management LLC raised its position in Gilead Sciences by 843.7% during the 2nd quarter. Anchor Investment Management LLC now owns 2,831 shares of the biopharmaceutical company’s stock worth $358,000 after buying an additional 2,531 shares during the last quarter. Bullseye Investment Management LLC purchased a new position in Gilead Sciences during the 2nd quarter worth approximately $2,085,000. Talon Private Wealth LLC acquired a new stake in Gilead Sciences during the 2nd quarter valued at approximately $212,000. Finally, Core Capital Management & Research inc. purchased a new stake in shares of Gilead Sciences in the 2nd quarter valued at $40,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company’s research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.